Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60.

PMID:
9732070
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Delavirdine: a review of its use in HIV infection.

Scott LJ, Perry CM.

Drugs. 2000 Dec;60(6):1411-44. Review.

PMID:
11152019
4.

[Predictive factors of virological response to primary antiretroviral treatment].

Faucher JF, Challier B, Chirouze C, Drobacheff C, Fischer P, Lang JM, Boyer L, May T, Froidure M, Chavanet P, Lescure FX, Strady C, Hoen B.

Presse Med. 2004 Mar 13;33(5):310-5. Review. French.

PMID:
15041876
5.

Studies of zidovudine in combination with didanosine and zalcitabine.

Jablonowski H.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S52-6. Review.

PMID:
8595509
6.
7.

Didanosine: an updated review of its use in HIV infection.

Perry CM, Noble S.

Drugs. 1999 Dec;58(6):1099-135. Review.

PMID:
10651392
8.

Measuring viral load in the clinical setting.

Harrigan R.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S34-40. Review.

PMID:
8595506
9.

Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis.

Chowers M, Gottesman BS, Leibovici L, Schapiro JM, Paul M.

Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):779-86. doi: 10.1007/s10096-010-0926-y. Review.

PMID:
20449621
10.

[Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida..

Enferm Infecc Microbiol Clin. 2012 Jun;30(6):e1-89. doi: 10.1016/j.eimc.2012.03.006. Spanish.

PMID:
22633764
11.

Advances in antiretroviral therapy and viral load monitoring.

Hammer SM.

AIDS. 1996 Dec;10 Suppl 3:S1-11. Review.

PMID:
8970706
12.

Zalcitabine.

Shelton MJ, O'Donnell AM, Morse GD.

Ann Pharmacother. 1993 Apr;27(4):480-9. Review.

PMID:
8097417
13.

Immunomodulatory effects of antiretroviral chemotherapy.

Schooley RT.

J Biol Regul Homeost Agents. 1995 Jul-Sep;9(3):110-3. Review.

PMID:
8782019
15.

Recent advances in antiretroviral therapy and HIV infection monitoring.

Schmit JC, Weber B.

Intervirology. 1997;40(5-6):304-21. Review.

PMID:
9675636
16.

Antiretroviral therapy in human immunodeficiency virus-infected individuals.

Spooner KM.

Adv Intern Med. 1998;43:373-402. Review. No abstract available.

PMID:
9506188
17.

Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.

Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A.

Cochrane Database Syst Rev. 2000;(3):CD002038. Review.

PMID:
10908523
18.

New approaches to using antiretroviral therapy for the management of HIV Infection.

Doran CM.

Ann Pharmacother. 1997 Feb;31(2):228-36. Review.

PMID:
9034425
19.

Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.

Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A.

Cochrane Database Syst Rev. 2000;(2):CD002038. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD002038.

PMID:
10796851
Items per page

Supplemental Content

Support Center